4 unchanged sentences
Amended and Restated Bylaws.
−Removed: Amendment No.
−Removed: 2 to Development and Manufacturing and Services Agreement, dated as of July 15, 2020, by and between the Company and Corden Pharma Brussels S.A.
−Removed: Offer Letter, dated July 16, 2020, between Rhythm Pharmaceuticals, Inc.
−Removed: Certification of the Prinicpal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.
+Added: Offer Letter, dated September 4, 2020, and Indefinite Term Employment Contract, dated October 5, 2020, between Rhythm Pharmaceuticals, Inc.
+Added: and Yann Mazabraud.
+Added: Separation Agreement, dated September 30, 2020, between Rhythm Pharmaceuticals, Inc.
+Added: and Nithya Desikan.
+Added: Certification of the Principal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.
Certification of the Principal Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.
10 unchanged sentences
** Furnished herewith.
−Removed: † Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Item 601(b)(10)(iv) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RHYTHM PHARMACEUTICALS, INC.
−Removed: August 3, 2020
+Added: November 2, 2020
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: August 3, 2020
+Added: November 2, 2020
/s/ Hunter C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.